Breast Cancer Fight

DALLAS, Jan. 4 /PRNewswire/ -- In early November, seven franchise industry professionals involved in WEBB, or Women Empowered By Business, participated in the Susan G. Komen's Breast Cancer 3-Day® 60-mile walk in Dallas, TX. The team, "Team SpiderWEBB," was sponsored by 25 franchisors, who helped them raise over $20 thousand for breast cancer awareness and research.  

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher. The findings was presented at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12 (Abstract 710)...  

New data suggest that breast cancer patients with HER2- and basal-molecular subtypes are more likely to respond to neoadjuvant chemotherapy than patients with luminal-type molecular subtype characteristics. The findings were released at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)...  

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings at the CTRC-AACR San Antonio Breast Cancer Symposium. Blackwell says the combination targeted therapy gave patients more than a four-month survival...  

Pfizer Inc. (NYSE: PFE) announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Neratinib is now part of Pfizer's expanded oncology portfolio, following the recent acquisition of Wyeth...  

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment. Women in the study had already received an average of seven...  

Incyte Corporation (Nasdaq:INCY) announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer The results suggest that, when compared to a historical control study of trastuzumab as monotherapy, INCB7839 in combination with trastuzumab provided improvements in time to progression and response rate in patients...  

NORTHBROOK, IL -- 12/29/09 -- AmpliVox announced an unprecedented corporate campaign to support the cause for Breast Cancer Awareness. To raise the bar on "being heard," AmpliVox donates one pink podium to every breast cancer awareness related pres..  

ImmunoGen, Inc (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710) T-DM1 comprises ImmunoGen?s DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group.  

ABC NewsTargeted Breast Cancer Drug Shrinks TumorsWebMDThe findings were presented at the San Antonio Breast Cancer Symposium. About 20% of breast cancer patients have HER2-positive cancers -- tumors that have ...More on what breast cancer treatment should be -- and what it often isLos Angeles Times (blog)Soy Consumption Appears to Help Breast-Cancer SurvivorsWall Street JournalExperimental drug kills breast cancer stem cellsReutersU.S. News...  

Cancer survivors and doctors in our area both say getting a mammogram as early as possible will save lives. That is why a recommendation to start mammograms at age 50 by a government panel is not sitting well with doctors at MCG and breast cancer survivors.  

SAN ANTONIO -- Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin. Link:  http://www.mayoclinic.org/news  

Grammy nominated rapper Flo Rida has teamed with the Grammy Foundation to perform at an event to support breast cancer awareness for women under 40 in Pittsburgh, Pennsylvania.   Flo Rida and Grammy nominated British act The Ting Tings will perform as part of B94's “Winter Blast.”   The proceeds from the event will be donated to the Glimmer of Hope Foundation, a Pittsburgh-based organization that has raised millions of dollars for breast...  

Bone Drugs Taken by Some Women May Lower Breast Cancer Risk, Studies SayNew York Times... it's possible there is an added benefit,” said Dr. Eric P. Winer, a breast cancer specialist at the Dana-Farber Cancer Institute in Boston. ...Targeted Therapy Prolongs Life in Patients With HER2-Positive Breast CancerScience Daily (press release)New Weapon in Breast Cancer Battle? Experts CautiousABC NewsStudies: Bone drugs may help prevent breast...  

Chemotherapy plus trastuzumab is better than chemotherapy alone in HER2-positive women. Everyone agrees with these new study results; after that, much is in contention. Medscape Medical News